For P&G: All statements, other than statements of historical fact included in this release, are forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on financial data, market assumptions and business plans available only as of the time the statements are made, which may become out of date or incomplete. We assume no obligation to update any forward-looking statement as a result of new information, future events or other factors. Forward-looking statements are inherently uncertain, and investors must recognize that events could differ significantly from our expectations. In addition to the risks and uncertainties noted in this release, there are certain factors that could cause actual results to differ materially from those anticipated by some of the statements made. These include: (i) the ability to achieve business plans, including with respect to lower income consumers and growing existing sales and volume profitably despite high levels of competitive activity, especially with respect to the product categories and geographical markets (including developing markets) in which the Company has chosen to focus; (ii) the ability to successfully execute, manage and integrate key acquisitions and mergers, including (a) the Domination and Profit Transfer Agreement with Wella, and (b) the Company's merger with The Gillette Company, and to achieve the cost and growth synergies in accordance with the stated goals of these transactions; (iii) the ability to manage and maintain key customer relationships; (iv) the ability to maintain key manufacturing and supply sources (including sole supplier and plant manufacturing sources); (v) the ability to successfully manage regulatory, tax and legal matters (including product liability, patent, and intellectual property matters as well as those related to the integration of Gillette and its subsidiaries), and to resolve pending matters within current estimates; (vi) the ability to successfully implement, achieve and sustain cost improvement plans in manufacturing and overhead areas, including the Company's outsourcing projects; (vii) the ability to successfully manage currency (including currency issues in volatile countries), debt, interest rate and commodity cost exposures; (viii) the ability to manage continued global political and/or economic uncertainty and disruptions, especially in the Company's significant geographical markets, as well as any political and/or economic uncertainty and disruptions due to terrorist activities; (ix) the ability to successfully manage competitive factors, including prices, promotional incentives and trade terms for products; (x) the ability to obtain patents and respond to technological advances attained by competitors and patents granted to competitors; (xi) the ability to successfully manage increases in the prices of raw materials used to make the Company's products; (xii) the ability to stay close to consumers in an era of increased media fragmentation; and (xiii) the ability to stay on the leading edge of innovation and maintain a positive reputation on our brands. For additional information concerning factors that could cause actual results to materially differ from those projected herein, please refer to our most recent 10-K, 10-Q and 8-K reports.
REFERENCES
(1) McClung MR et al. The Effect of risedronate on risk of clinical fracture among patients with prior hip fracture. ASBMR. 2007. Honolulu. Abstract.
(2) McClung MR et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344: 333-340.
(3) Klotzbuecher, CM, et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J of Bone Min Res 2000;15: 721-739.
(4) Sheryl L.et al. Lack of diagnosis and treatment of osteoporosis in men and women after hip fracture. Pharmacotherapy 2003;23(2): 190-198.
(5) Orwig DL, et al. Treatment of osteoporosis following a hip fracture: sending results of bone densitometry to primary care physicians does not increase use of pharmacologic therapy (abstr). J Bone Miner Res 2001;15(suppl 1): SA323.
(6) Melton LJ et al. Perspective. How many women have osteoporosis? J Bone Miner Res 1992; 7: 1005-1010
(7) Kanis J A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-36
(8) EFFO and NOF Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int 1997;7:1.
(9) International Osteoporosis Foundation. Osteoporosis in the European Community: a call to action. An audit of policy developments since 1998. International Osteoporosis Foundation 2001
(10) Kanis JA, Johnell O. Requirements for DXA for the management of osteoporosis in Europe. Osteoporosis Int 2005;16: 229-38
(11) Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002; 50: 1644-1650
(12) Magaziner J, Simonsick EM, Kashner TM, et al. Predictors of functional recovery one year following hospital discharge for hip fracture: a prospective study. J Gerontol 1990; 45: M101-M107
(13) European Commission Report on Osteoporosis in the European Community. Action for prevention. Luxembourg: Office for Official Publications of the European Communities 1998
(14) World Health Organisation. Prevention and management of osteoporosis. WHO Technical Report Series 921. Geneva: World Health Organisation 2003.
For further information please contact:
Helen Crow
Ketchum
+44-(0)7787-533-023
Peter Impey
Ketchum
+44-(0)7976-734-493
For further information please contact: Helen Crow, Ketchum, +44-(0)7787-533-023; Peter Impey, Ketchum, +44-(0)7976-734-493
